United Kingdom Molecular Forensics Market Size & Outlook, 2026-2034
United Kingdom Molecular Forensics Market Insights
- As highlighted in Reed Intelligence analysis, the United Kingdom Molecular Forensics Market, worth USD 619.32 Million in 2025, is forecasted to achieve USD 1478.12 Million by 2034.
- The United Kingdom market is anticipated to grow at a CAGR of 10.19% during the period 2026–2034.
- By 2025, PCR-Based Analysis represented the largest share of the Technology market size.
- Microarray Technology is expected to remain the key growth driver within Technology, registering the fastest CAGR during the forecast period.
Source: RI Analysis Company Publications, Primary Interviews.
Other Key Findings
- In 2025, United Kingdom accounted for 7.36% of the global Molecular Forensics Market size.
- By 2034, United States is expected to lead the global Molecular Forensics Market in terms of market size.
- Within Europe, Germany is projected to dominate the regional Molecular Forensics Market size by 2034.
- France is identified as the fastest-growing market in Europe, anticipated to reach USD 979.13 Million by 2034.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2025 |
| Study Period | 2022-2034 |
| Historical Period | 2022-2024 |
| Forecast Period | 2026-2034 |
| Market Size In 2025 | USD 619.32 Million |
| Market Size In 2034 | USD 1478.12 Million |
| Largest segment | PCR-Based Analysis |
| Units | Revenue in USD Million |
| CAGR | 10.19% (2026-2034) |
| Segmnetation Covered | |
| Technology |
|
| Application |
|
| End Use |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
United Kingdom Molecular Forensics Market Technology 2026-2034 (USD Million)
| Technology | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PCR-Based Analysis | XX.x | XX.x | XX.x | 247.79 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Next-Generation Sequencing | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Capillary Electrophoresis | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Microarray Technology | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
United Kingdom Molecular Forensics Market Application 2026-2034 (USD Million)
| Application | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Criminal Investigation | XX.x | XX.x | XX.x | 238.62 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Paternity Testing | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Biodefense and Pathogen Tracing | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Food Authentication | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Wildlife Forensics | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
United Kingdom Molecular Forensics Market End Use 2026-2034 (USD Million)
| End Use | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Government Forensic Laboratories | XX.x | XX.x | XX.x | 305.82 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Private Forensic Laboratories | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Academic and Research Institutions | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Healthcare and Biosurveillance Agencies | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.